HSAC - Health Sciences Acquisitions Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
11.12
+0.09 (+0.82%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close11.03
Open11.15
Bid11.07 x 900
Ask11.12 x 900
Day's Range11.01 - 11.49
52 Week Range9.57 - 11.49
Volume24,760
Avg. Volume161,434
Market Cap160M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Health Sciences Acquisitions Corporation Sets Date for Special Meeting of Stockholders to Vote on Transaction with Immunovant Sciences Ltd.

    Health Sciences Acquisitions Corporation ("HSAC," NASDAQ: HSAC), a special purpose acquisition company sponsored by RTW Investments, LP, announced today that it has set a record date and a meeting date for the special meeting of its stockholders to, among other things, consider and vote on a proposal to approve the transactions contemplated by the previously announced share exchange agreement pursuant to which HSAC will acquire 100% of the issued and outstanding shares in Immunovant Sciences Ltd., a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases.

  • PR Newswire

    Health Sciences Acquisitions Corporation and Immunovant to Host Joint Conference Call for the Investment Community on Friday, October 11, at 8:30am EDT

    NEW YORK and LONDON, Oct. 8, 2019 /PRNewswire/ -- Health Sciences Acquisitions Corporation ("HSAC," NASDAQ: HSAC), a special purpose acquisition company sponsored by RTW Investments, and Immunovant Sciences Ltd. ("Immunovant"), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced that they will host a joint conference call to discuss their planned merger. The conference call will take place on Friday, October 11, at 8:30am EDT.

  • PR Newswire

    Immunovant to Merge with Health Sciences Acquisitions Corporation, Creating New Publicly Listed FcRn-Focused Company

    NEW YORK and LONDON, Oct. 2, 2019 /PRNewswire/ -- Health Sciences Acquisitions Corporation ("HSAC," NASDAQ: HSAC), a special purpose acquisition company sponsored by RTW Investments, and Immunovant Sciences Ltd. ("Immunovant"), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced that they have entered into a definitive share exchange agreement ("SEA"). HSAC will acquire 100% of the issued and outstanding shares in Immunovant.